IGNITE!
Joshua Davis, MD
Penn State Health - Milton S. Hershey Medical Center
This ignite session will review 10 of the most relevant new drug approvals from 2018 for the emergency physican. There may be additions/changes in the next 6 months, but current candidates include:
Xofluza (baloxivir -- Japanese Tamiflu)
Epidiolex (CBD for epilepsy)
Aimovig/Emgality/Ajovy (CGRP inhibitors for chronic migraine)
Zemdri (plazomicin, new antibiotic)
Orilissa (GRH antagonist for endometriosis pain)
Takhzyro (another new med or hereditary angioedema)
XeravaNuzyra (Eravacycline/omadacycline, new antibiotics)
Aemcolo (antibiotic to treat traveler's diarrhea)
Motegrity (prucalopride to treat constipation)
Lokelma (sdium zirconium cyclosilicate for hyperkalemia)
This IGNITE will focus on the high yield ED physicians need to know about these drugs. I.e., indications/mechanism for antibiotics, side effects for chronic medications, possibility of use or availability in the ED. And some comparisons to present day drugs (Does Xofluza work any better than Tamiflu. .. does Lokelma work any better than Kayexelate?)